Physician profile
Kusum Bhandari
NPI 1700952884
$7,937.05
in general payments reported to CMS, 2019-2025
41 companies · $1,178 in 2025
The $1,178 reported for 2025 was more than what 81% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $704 · 2020: $533 · 2021: $1,572 · 2022: $1,184 · 2023: $1,415 · 2024: $1,351 · 2025: $1,178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,834 · Education: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,834.42 |
| Education | $109.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,089.06 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $650.95 | 2019-2025 | Tavneos, Krystexxa, Aranesp |
| Otsuka America Pharmaceutical, INC. | $611.56 | 2019-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $568.16 | 2021-2025 | |
| Veloxis Pharmaceuticals, INC. | $502.04 | 2019-2025 | Envarsus |
| Daiichi Sankyo INC. | $397.60 | 2019-2025 | Injectafer |
| Vifor Pharma, INC. | $388.49 | 2019-2025 | Veltassa |
| Travere Therapeutics, INC. | $361.23 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $332.27 | 2023-2025 | |
| Horizon Therapeutics Plc | $319.92 | 2021-2023 | Krystexxa |
| Opko Pharmaceuticals, LLC | $279.99 | 2019-2024 | Rayaldee |
| Mallinckrodt Hospital Products INC. | $241.34 | 2020-2025 | Terlivaz |
| Calliditas Therapeutics US INC. | $180.62 | 2022-2025 | Tarpeyo |
| Ani Pharmaceuticals, INC. | $168.62 | 2022-2024 | Purified Cortrophin Gel |
| Glaxosmithkline, LLC. | $146.35 | 2021-2025 | Benlysta |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kusum Bhandari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.